Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1192-1200

  Falchook, Gerald S ^a   Fu, Siqing ^a   Naing, Aung ^a   Hong, David S ^a   Hu, Wei ^a   Moulder, Stacy ^a   Wheler, Jennifer J ^a   Sood, Anil K ^a   Bustinza Linares, Ernesto ^b   Parkhurst, Kristin L ^a   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Azacitidine; Carboplatin; Histone deacetylase inhibition; Methylation; Valproic acid

Indexed keywords

AZACITIDINE; CARBOPLATIN; DEATH RECEPTOR 4; PLATINUM COMPLEX; VALPROIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER RESISTANCE; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; DIZZINESS; DNA METHYLATION; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPOTENSION; INFECTION; LARYNX SQUAMOUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MENTAL FUNCTION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SEBACEOUS CARCINOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THYMUS CANCER; UTERINE CERVIX CANCER; VOMITING;

ACETYLATION; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARBOPLATIN; DNA METHYLATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; VALPROIC ACID;

EID: 84884812613     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0003-3     Document Type: Article

References (39)

1. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428. doi: 10.1038/nrg816
2. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33. doi: 10.1038/nrg1748
3. Mutskov V, Felsenfeld G (2004) Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 23:138-149. doi: 10.1038/sj.emboj.7600013
4. Masumoto H, Hawke D, Kobayashi R, Verreault A (2005) A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436:294-298. doi: 10.1038/nature03714
5. Markman M (2008) Pharmaceutical management of ovarian cancer: current status. Drugs 68:771-789
6. Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N (2008) Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 6:766-794
7. Markman M (2008) Second-line therapy for ovarian cancer. Clin Adv Hematol Oncol 6:421-422
8. Bukowski RM, Ozols RF, Markman M (2007) The management of recurrent ovarian cancer. Semin Oncol 34:S1-S15. doi: 10.1053/j.seminoncol.2007.03.012
9. Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-Azacytidine and 5-Aza-2′-deoxycytidine. J Biol Chem 257:2041-2048
10. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H (2006) Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28:1233-1241
11. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107. doi: 10.1038/5047
12. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S (2009) Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 200(177):e171-e179. doi: 10.1016/j.ajog.2008.08.030
13. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr (2011) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117:1661-1669. doi: 10.1002/cncr.25701
14. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH (2008) Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 99:1218-1226. doi: 10.1111/j.1349-7006.2008.00793.x
15. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1/2 study of the combination of 5-Aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279. doi: 10.1182/blood-2006-03-009142
16. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948-3956. doi: 10.1200/JCO.2005.11.981
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
18. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181. doi: 10.1016/S1053-4296(03)00031-6
19. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R (2008) Phase I study of epigenetic modulation with 5-Azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14:6296-6301. doi: 10.1158/1078-0432.CCR-08-1247
20. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116:4043-4053. doi: 10.1002/cncr.25204
21. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-Associated ovarian carcinoma. Cancer 97:2187-2195. doi: 10.1002/cncr.11310
22. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115. doi: 10.1038/nature06548
23. Strathdee G, MacKean MJ, Illand M, Brown R (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341. doi: 10.1038/sj.onc.1202540
24. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10:4420-4426. doi: 10.1158/1078-0432. CCR-03-0732
25. Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L (2004) Hypermethylation of the death-Associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res 2:685-691
26. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967. doi: 10.1158/0008-5472.CAN-05-1187
27. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574. doi: 10.1038/nm852
28. Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15:3938-3946. doi: 10.1158/1078-0432.CCR-08-2783
29. Griffiths EA, Gore SD (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45:23-30. doi: 10.1053/j.seminhematol.2007.11.007
30. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G (2007) Safety and clinical activity of the combination of 5-Azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308. doi: 10.1182/blood-2007-03-078576
31. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884-3891. doi: 10.1200/JCO.2006.09.4169
32. Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758-763. doi: 10.1038/sj.bjc.6604932
33. Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74:659-671. doi: 10.1016/j.bcp.2007.04.007
34. Qin T, Jelinek J, Si J, Shu J, Issa JP (2009) Mechanisms of resistance to 5-Aza-2′-deoxycytidine in human cancer cell lines. Blood 113:659-667. doi: 10.1182/blood-2008-02-140038
35. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B (2003) Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3:89-95
36. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49:690-695. doi: 10.1080/10428190701882146
37. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138. doi: 10.1038/72785
38. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168-174
39. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:141-149. doi: 10.1038/ng892